Genelux Announces Publication Of Translational And Clinical Findings From Phase 1b/2 VIRO-15 Trial Of Olvi-Vec-Primed Immunochemotherapy In

Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from Phase 2 VIRO-15 trial - - Data demonstrate Olvi-Vec–mediated modulation of the tumor microenvironment and immune activation - - Translational analyses identify gene expression changes associated with chemotherapy sensitization, anticancer response, and favorable prognosis following Olvi-Vec-primed immunochemotherapy treatment - WESTLAKE VILLAGE, Calif.,, June 30, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX ), a late clinical-stage immuno-oncology company, today announced the publication of translational and clinical findings from its Phase 1b/2 VIRO-15 trial of Olvi-Vec-primed immunochemotherapy in heavily pretreated patients with platinum-resistant/refractory ovarian cancer (PRROC). The data were presented in Gynecologic Oncol...